Literature DB >> 18196271

Influence of preoperative core biopsies on uPA/PAI-1 expression in breast cancer tissue.

Susanne Haas1, Tjoung-Won Park, Jens Claus Hahne, Hans-Peter Fischer.   

Abstract

The urokinase-type plasminogen activator (uPA) and the plasminogen activator inhibitor-1 (PAI-1) are involved in tumor invasion and metastasis as well as wound healing and inflammation. We investigated the impact of tissue injury by preoperative sampling on the level of uPA/PAI-1 in paraffin tissue of 55 breast cancer cases by immunohistochemistry. The tumor area surrounding the biopsy channel was compared with distant intact tumor tissue. uPA and PAI-1 were constantly expressed by the tumor cells. Fibroblastic expression was higher in the tumor area surrounding the biopsy channel than in intact tissue with 47 vs 29 positive cases for uPA (p<0.001) and 35 vs 25 positive cases for PAI-1 (p=0.055). A decrease in fibroblastic enzyme expression from the biopsy area to the intact tumor tissue was seen in 21 cases for uPA and 16 cases for PAI-1. This difference was most evident in cases with an interval of 6 days and longer between biopsy and surgery. In conclusion, fibroblastic inflammatory reaction around the biopsy channel affects stromal uPA and PAI-1 expression, which possibly leads to falsely increased enzyme levels in ELISA. Tissue specimen for ELISA analysis should not be taken from the tumor area around the biopsy channel in the resection specimen.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18196271     DOI: 10.1007/s00428-007-0563-8

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  19 in total

1.  Different patterns of inflammation and prognosis in invasive carcinoma of the breast.

Authors:  A H S Lee; C E Gillett; K Ryder; I S Fentiman; D W Miles; R R Millis
Journal:  Histopathology       Date:  2006-05       Impact factor: 5.087

2.  Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.

Authors:  M J Duffy; D Reilly; C O'Sullivan; N O'Higgins; J J Fennelly; P Andreasen
Journal:  Cancer Res       Date:  1990-11-01       Impact factor: 12.701

Review 3.  The plasminogen activation system in tumor growth, invasion, and metastasis.

Authors:  P A Andreasen; R Egelund; H H Petersen
Journal:  Cell Mol Life Sci       Date:  2000-01-20       Impact factor: 9.261

4.  Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer.

Authors:  B S Nielsen; M Sehested; S Duun; F Rank; S Timshel; J Rygaard; M Johnsen; K Danø
Journal:  Lab Invest       Date:  2001-11       Impact factor: 5.662

5.  Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer.

Authors:  S Ganesh; C F Sier; G Griffioen; H J Vloedgraven; A de Boer; K Welvaart; C J van de Velde; J H van Krieken; J H Verheijen; C B Lamers
Journal:  Cancer Res       Date:  1994-08-01       Impact factor: 12.701

6.  Plasminogen activation in healing human wounds.

Authors:  B M Schäfer; K Maier; U Eickhoff; R F Todd; M D Kramer
Journal:  Am J Pathol       Date:  1994-06       Impact factor: 4.307

7.  Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer.

Authors:  C Pyke; E Ralfkiaer; K Tryggvason; K Danø
Journal:  Am J Pathol       Date:  1993-02       Impact factor: 4.307

8.  A novel coculture technique demonstrates that normal human prostatic fibroblasts contribute to tumor formation of LNCaP cells by retarding cell death.

Authors:  A F Olumi; P Dazin; T D Tlsty
Journal:  Cancer Res       Date:  1998-10-15       Impact factor: 12.701

Review 9.  Tumor-associated urokinase-type plasminogen activator: biological and clinical significance.

Authors:  M Schmitt; F Jänicke; N Moniwa; N Chucholowski; L Pache; H Graeff
Journal:  Biol Chem Hoppe Seyler       Date:  1992-07

Review 10.  Plasminogen activator inhibitor type 1 in cancer: therapeutic and prognostic implications.

Authors:  H Pappot; H Gårdsvoll; J Rømer; A N Pedersen; J Grøndahl-Hansen; C Pyke; N Brünner
Journal:  Biol Chem Hoppe Seyler       Date:  1995-05
View more
  5 in total

1.  Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections.

Authors:  Berit Maria Müller; Jan C Brase; Franziska Haufe; Karsten E Weber; Jan Budzies; Christoph Petry; Judith Prinzler; Ralf Kronenwett; Manfred Dietel; Carsten Denkert
Journal:  J Clin Pathol       Date:  2012-03-23       Impact factor: 3.411

2.  Core needle biopsy of breast cancer tumors increases distant metastases in a mouse model.

Authors:  Edward Gitau Mathenge; Cheryl Ann Dean; Derek Clements; Ahmad Vaghar-Kashani; Steffany Photopoulos; Krysta Mila Coyle; Michael Giacomantonio; Benjamin Malueth; Anna Nunokawa; Julie Jordan; John D Lewis; Shashi Ashok Gujar; Paola Marcato; Patrick W K Lee; Carman Anthony Giacomantonio
Journal:  Neoplasia       Date:  2014-11-20       Impact factor: 5.715

3.  High Expression of Urokinase-Type Plasminogen Activator Is Associated with Lymph Node Metastasis of Invasive Ductal Carcinoma of the Breast.

Authors:  Eun Young Kim; Sung-Im Do; Keehoon Hyun; Yong Lai Park; Dong-Hoon Kim; Seoung Wan Chae; Jin Hee Sohn; Chan Heun Park
Journal:  J Breast Cancer       Date:  2016-06-24       Impact factor: 3.588

4.  An ultra-sensitive immunoassay for quantifying biomarkers in breast tumor tissue.

Authors:  Carol B Fowler; Yan-Gao Man; Jeffrey T Mason
Journal:  J Cancer       Date:  2014-01-05       Impact factor: 4.207

5.  Integration of Serum Protein Biomarker and Tumor Associated Autoantibody Expression Data Increases the Ability of a Blood-Based Proteomic Assay to Identify Breast Cancer.

Authors:  Meredith C Henderson; Alan B Hollingsworth; Kelly Gordon; Michael Silver; Rao Mulpuri; Elias Letsios; David E Reese
Journal:  PLoS One       Date:  2016-08-10       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.